CD274 and non-small cell lung carcinoma: In Keynote 024,9, 10 pembrolizumab significantly prolonged progression‐free survival (PFS) and overall survival (OS) of patients with advanced NSCLC and PD‐L1 tumor proportion score (TPS) ≥50% (Table 1).